|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
KR100335584B1
(ko)
|
1992-10-28 |
2002-11-29 |
제넨테크, 인코포레이티드 |
혈관내피세포성장인자에대한길항제
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
US5804396A
(en)
|
1994-10-12 |
1998-09-08 |
Sugen, Inc. |
Assay for agents active in proliferative disorders
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
CN104231078A
(zh)
|
1997-04-07 |
2014-12-24 |
基因技术股份有限公司 |
抗-血管内皮生长因子的抗体
|
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
DE19937264A1
(de)
|
1999-08-06 |
2001-02-15 |
Deutsches Krebsforsch |
F¶v¶-Antikörper-Konstrukte
|
|
RS20150135A1
(sr)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
Tretman sa anti-vegf antitelima
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
EP2717895A1
(en)
|
2011-06-08 |
2014-04-16 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
|
CN104245726A
(zh)
|
2012-03-29 |
2014-12-24 |
奥瑞基尼探索技术有限公司 |
来自人pd1的bc环的免疫调节环状化合物
|
|
US9175082B2
(en)
|
2012-05-31 |
2015-11-03 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
RS61400B1
(sr)
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
TR201811077T4
(tr)
|
2013-09-06 |
2018-08-27 |
Aurigene Discovery Tech Ltd |
İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri.
|
|
RS57508B1
(sr)
|
2013-09-06 |
2018-10-31 |
Aurigene Discovery Tech Ltd |
1,2,4-derivati oksadiazola kao imunomodulatori
|
|
MX2016002970A
(es)
|
2013-09-06 |
2016-10-07 |
Aurigene Discovery Tech Ltd |
Compuestos peptidomimeticos ciclicos como inmunomoduladores.
|
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
US10570202B2
(en)
|
2014-02-04 |
2020-02-25 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
US10695426B2
(en)
|
2014-08-25 |
2020-06-30 |
Pfizer Inc. |
Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
CA2968680A1
(en)
|
2014-12-02 |
2016-06-09 |
Celgene Corporation |
Combination therapies
|
|
US20170363614A1
(en)
|
2014-12-22 |
2017-12-21 |
Enumeral Biomedical Holdings, Inc. |
Methods For Screening Therapeutic Compounds
|
|
DK3294770T4
(da)
|
2015-05-12 |
2024-05-21 |
Hoffmann La Roche |
Terapeutiske og diagnostiske fremgangsmåder til cancer
|
|
EP3303632B2
(en)
|
2015-05-29 |
2023-05-10 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
CA3009852A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20180099768A
(ko)
|
2015-12-30 |
2018-09-05 |
노파르티스 아게 |
증진된 효능을 갖는 면역 이펙터 세포 요법
|
|
EP3774914A2
(en)
|
2018-04-13 |
2021-02-17 |
Affimed GmbH |
Nk cell engaging antibody fusion constructs
|
|
CA3120200A1
(en)
*
|
2018-11-15 |
2020-05-22 |
Personal Genome Diagnostics Inc. |
Method of improving prediction of response for cancer patients treated with immunotherapy
|
|
US20220154295A1
(en)
*
|
2019-03-27 |
2022-05-19 |
The Johns Hopkins University |
Methods and materials for assessing and treating cancer
|